Orexigen Therapeutics – Orexigen Therapeutics, Inc. Amendment No. 2 to Employment Agreement June 16, 2016 (August 5th, 2016)
Reference is made to the EMPLOYMENT AGREEMENT (the Agreement) dated March 30, 2015 by and between OREXIGEN THERAPEUTICS, INC. (Orexigen or the Company) with its principal place of business located at 3344 N. Torrey Pines Ct., Suite 200, La Jolla, CA 92037 and THOMAS CANNELL (Executive), and AMENDMENT NO. 1 TO THE EMPLOYMENT AGREEMENT dated February 2, 2016 (the First Amendment). All capitalized terms used herein and not otherwise defined shall have the meanings assigned to such terms in the Agreement.
Orexigen Therapeutics – Orexigen Announces Strategic Acquisition of All U.S. Rights to Contrave(r), the Market Leading Branded Anti-Obesity Prescription Medicine Acquisition Magnifies Projected Long-Term Corporate Profitability and Opens Multiple Paths for Shareholder Value Creation Company Issues $165 Million in Convertible Senior Secured Notes to Fund Orexigen Also Today Announced Progress Toward European Commercialization Plan With Valeant 19 Country Central and Eastern European Partnership Orexigen to Host Conference Call Today at 8:30 a.m. Eastern Time (March 15th, 2016)
San Diego, CA, March 15, 2016 - Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced it has entered into an agreement with Takeda Pharmaceutical Company Limited to acquire the United States rights to Contrave(r) (naltrexone HCl / bupropion HCl extended release), the market leading branded prescription medicine for the treatment of obesity. The acquisition is subject to the parties' receipt of clearance under the Hart-Scott-Rodino Antitrust Improvement Act ("HSR Act"). Upon completion of the acquisition, including the agreed upon transition period, Orexigen will own all rights to Contrave in nearly all global territories.